BIOMAT Database Logo BIOMAT Database Logo

Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. 1998

R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan.

To evaluate the effect of pioglitazone on insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) patients, a double-blind placebo-controlled trial was carried out with 30 NIDDM patients. Twenty-one subjects, three on diet alone and 18 on sulfonylurea (SU), orally received 30 mg pioglitazone once daily for 12 weeks. Nine subjects, one on diet alone and eight on SU, received a matching placebo once daily for 12 weeks. Euglycemic (5.2 mmol/l) hyperinsulinemic (1200 pmol/l) clamp combined with an oral glucose load (OGL) was performed before and after 3-month treatment with pioglitazone or placebo to determine insulin-stimulated glucose disposal and splanchnic glucose uptake (SGU). No significant differences existed in the patients' characteristics, including age and body mass index, between the two study groups. The pioglitazone treatment increased the mean glucose infusion rate (GIR) prior to OGL from 8.2 +/- 2.2 to 9.2 +/- 2.0 mg/kg.min (mean +/- SD, P = 0.003) and increased the SGU rate from 28.5 +/- 19.4 to 59.4 +/- 27.1% (P = 0.010). The placebo treatment produced no significant changes in either GIR or SGU after treatment. A significant difference (P = 0.042) was observed in change of SGU between the pioglitazone and placebo treatment groups. In conclusion, the results indicate that pioglitazone is effective for ameliorating insulin resistance in NIDDM by enhancing SGU as well as peripheral glucose uptake.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077205 Pioglitazone A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS. Pioglitazone Hydrochloride,5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione,AD 4833,AD-4833,Actos,U 72107A,U-72107A,U72,107A,AD4833,U72107A

Related Publications

R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
November 1997, The Tohoku journal of experimental medicine,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus.
November 1997, The Journal of clinical investigation,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus.
April 1998, Endocrine journal,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.
July 1985, The Journal of clinical investigation,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus.
January 1988, Metabolism: clinical and experimental,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus.
January 1996, Annals of internal medicine,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Australian Diabetes Screening Study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus.
December 1997, Metabolism: clinical and experimental,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Determination and kinetic analysis of non-insulin mediated glucose uptake in type 1 (insulin-dependent) diabetes mellitus.
January 1989, Diabetologia,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Age, glucose intolerance, and non-insulin-dependent diabetes mellitus.
April 1985, Journal of the American Geriatrics Society,
R Kawamori, and M Matsuhisa, and J Kinoshita, and K Mochizuki, and M Niwa, and T Arisaka, and M Ikeda, and M Kubota, and M Wada, and T Kanda, and M Ikebuchi, and R Tohdo, and Y Yamasaki
Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus.
December 1994, Metabolism: clinical and experimental,
Copied contents to your clipboard!